Literature DB >> 16191872

Treatment of livedoid vasculopathy with short-cycle intravenous immunoglobulins.

Gerard Pitarch, Mercedes Rodríguez-Serna, Arantxa Torrijos, Vicente Oliver, José Miguel Fortea.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16191872     DOI: 10.1080/00015550510027865

Source DB:  PubMed          Journal:  Acta Derm Venereol        ISSN: 0001-5555            Impact factor:   4.437


× No keyword cloud information.
  6 in total

Review 1.  Efficacy and safety of intravenous immunoglobulin for treating refractory livedoid vasculopathy: a systematic review.

Authors:  Yimeng Gao; Hongzhong Jin
Journal:  Ther Adv Chronic Dis       Date:  2022-05-22       Impact factor: 4.970

2.  Livedoid vasculopathy associated with combined prothrombin G20210A and factor V (Leiden) heterozygosity and MTHFR C677T homozygosity.

Authors:  Noha A Irani-Hakime; Farid Stephan; Raghid Kreidy; Isabelle Jureidini; Wassim Y Almawi
Journal:  J Thromb Thrombolysis       Date:  2008-03-23       Impact factor: 2.300

3.  A Phase II Multicenter Trial With Rivaroxaban in the Treatment of Livedoid Vasculopathy Assessing Pain on a Visual Analog Scale.

Authors:  Attyla Drabik; Carina Hillgruber; Tobias Goerge
Journal:  JMIR Res Protoc       Date:  2014-12-10

Review 4.  Livedoid vasculopathy: A multidisciplinary clinical approach to diagnosis and management.

Authors:  Asli Bilgic; Salih Ozcobanoglu; Burcin Cansu Bozca; Erkan Alpsoy
Journal:  Int J Womens Dermatol       Date:  2021-09-02

Review 5.  Comparative Efficacy of Rivaroxaban and Immunoglobulin Therapy in the Treatment of Livedoid Vasculopathy: A Systematic Review.

Authors:  Shivana Ramphall; Swarnima Rijal; Vishakh Prakash; Heba Ekladios; Jiya Mulayamkuzhiyil Saju; Naishal Mandal; Nang I Kham; Rabia Shahid; Shaili S Naik; Sathish Venugopal
Journal:  Cureus       Date:  2022-08-27

6.  Systemic lupus erythematosus with refractory ulcerated livedoid vasculopathy: Successful treatment with intravenous immunoglobulin and warfarin.

Authors:  Katsunobu Yoshioka; Chiharu Tateishi; Hiromi Kato; Ko-Ron Chen
Journal:  Clin Case Rep       Date:  2018-09-12
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.